Neutrophilic dermatosis complicating lenalidomide therapy

Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of myelodysplastic syndrome and is currently under investigative use for metastatic melanoma. We...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2009-10, Vol.61 (4), p.709-710
Main Authors: Thieu, Khanh P., BS, Rosenbach, Misha, MD, Xu, Xiaowei, MD, PhD, Kist, Joseph M., MD
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Biological and medical sciences
Biopsy
Dermatology
Female
Humans
lenalidomide
Medical sciences
Middle Aged
Multiple Myeloma - drug therapy
neutrophilic dermatosis
Skin - pathology
Skin involvement in other diseases. Miscellaneous. General aspects
Sweet Syndrome - chemically induced
Sweet Syndrome - pathology
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of myelodysplastic syndrome and is currently under investigative use for metastatic melanoma. We present a case of neutrophilic dermatosis involving predominantly the lower extremities in a patient receiving lenalidomide therapy for multiple myeloma.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2008.12.011